Published • loading... • Updated
WuXi Vaccines' Drug Substance Facility Receives Brazil ANVISA GMP Certification for Dengue Vaccine Manufacturing
- WuXi Vaccines' drug substance facility MFG23 in Suzhou received Good Manufacturing Practices certification from Brazil's Agência Nacional de Vigilância Sanitária for dengue vaccine manufacturing.
- The MFG23 facility supports Instituto Butantan's dengue vaccine production project by providing integrated manufacturing services.
- ANVISA granted certification after inspecting the manufacturing site, quality assurance, control, and utilities at MFG23.
- WuXi Vaccines will provide end-to-end manufacturing and quality control services for Instituto Butantan's 5-dose dengue vaccine under a commercial agreement.
Insights by Ground AI
30 Articles
30 Articles
InsideNoVA.com+29 Reposted by 29 other sources
WuXi Vaccines' Drug Substance Facility Receives Brazil ANVISA GMP Certification for Dengue Vaccine Manufacturing
SUZHOU, China, May 26, 2026 /PRNewswire/ -- WuXi Vaccines, a wholly-owned subsidiary of WuXi Biologics, dedicated to vaccine Contract Development and Manufacturing Organization (CDMO), announced today that its drug substance facility (MFG23) located in Suzhou has received Good Manufacturing Practices…
Coverage Details
Total News Sources30
Leaning Left4Leaning Right4Center15Last UpdatedBias Distribution65% Center
Bias Distribution
- 65% of the sources are Center
65% Center
L 18%
C 65%
R 17%
Factuality
To view factuality data please Upgrade to Premium
